ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 473,73
0,32%
Dow Jones
40 659,76
0,24%
DAX
18 348,02
0,10%
Brent Oil
78,565
-0,34%
Bitcoin
58 122,75
-0,80%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) Actualités

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:JNJ
DateHeureSourceTitreSymboleSociété
15/08/202412h05IH Market NewsGoogle Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
15/08/202412h05IH Market NewsGoogle Forced to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
13/08/202411h43IH Market NewsDell Stock Slide Offers Opportunities; Trump and Musk hold talks on X; GM Restructures China Operations, and MoreNYSE:JNJJohnson and Johnson
09/08/202422h35Edgar (US Regulatory)Form 13F-HR - Quarterly report filed by institutional managers, HoldingsNYSE:JNJJohnson and Johnson
07/08/202423h00PR Newswire (US)Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of MedicineNYSE:JNJJohnson and Johnson
31/07/202403h06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:JNJJohnson and Johnson
31/07/202400h42PR Newswire (US)DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligibleNYSE:JNJJohnson and Johnson
30/07/202412h00IH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:JNJJohnson and Johnson
29/07/202422h00Business WireJohnson & Johnson to Participate in the 2024 Wells Fargo Healthcare ConferenceNYSE:JNJJohnson and Johnson
26/07/202415h38Business WireCourts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step PlanNYSE:JNJJohnson and Johnson
26/07/202415h05Business WireFINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation PlanNYSE:JNJJohnson and Johnson
26/07/202412h07IH Market NewsAlphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in ChinaNYSE:JNJJohnson and Johnson
25/07/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:JNJJohnson and Johnson
23/07/202422h00Business WireJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
22/07/202417h59Business WireLawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy PlanNYSE:JNJJohnson and Johnson
22/07/202414h00PR Newswire (US)Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionNYSE:JNJJohnson and Johnson
17/07/202414h14Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
17/07/202412h30IH Market NewsTech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory DropNYSE:JNJJohnson and Johnson
17/07/202412h28IH Market NewsSpirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings UpdatesNYSE:JNJJohnson and Johnson
17/07/202412h25Business WireJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2024NYSE:JNJJohnson and Johnson
17/07/202412h20Business WireJohnson & Johnson reports Q2 2024 resultsNYSE:JNJJohnson and Johnson
11/07/202413h30Business WireJohnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26NYSE:JNJJohnson and Johnson
09/07/202423h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
03/07/202414h00PR Newswire (Canada)Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNYSE:JNJJohnson and Johnson
03/07/202414h00PR Newswire (Canada)Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules pNYSE:JNJJohnson and Johnson
02/07/202413h30PR Newswire (US)CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyNYSE:JNJJohnson and Johnson
28/06/202417h30PR Newswire (US)Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsNYSE:JNJJohnson and Johnson
28/06/202400h46Business WireLawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in PurdueNYSE:JNJJohnson and Johnson
21/06/202413h30Business WireJohnson & Johnson Completes Acquisition of Proteologix, Inc.NYSE:JNJJohnson and Johnson
20/06/202422h30PR Newswire (US)Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's diseaseNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Dernières Valeurs Consultées

EU
BEL20
Bel 20
EU
VIV
Vivendi
EU
SGO
Cie de SaintGobain
NASDAQ
NVDA
NVIDIA
EU
MC
Lvmh Moet Hennessy Louis...
FTSE
UKX
FTSE 100
COIN
SOLUSD
Solana
EU
PX1
CAC 40
EU
DG
Vinci
NASDAQ
AMZN
Amazon.com
NYSE
DIS
Walt Disney
NYSE
KO
Coca Cola
COIN
BTCUSD
Bitcoin
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés